Yusuf Uysal, MD, Salih Altun, MD, Güngör Sobacı, MD, M. Zeki Bayraktar, MD, Gülhane Medical Faculty Department of Ophthalmology, Ankara, Turkey


To evaluate the efficacy and safety of intravitreal injection of 4mg of triamcinolone acetonide for diffuse diabetic macular edema.


Twenty five patients were unresponsive to laser photocoagulation in group I; fifteen patients without laser photocoagulation in group II prospectively evaluated. Visual outcomes were compared.


At least 3 months follow-up were obtained in the groups (range: 3 to12 months in group I, 3 to 8 months in group II). Visual benefit (visual acuity increase in 2 or more Snellen lines) from this treatment regimen were more common in patients with similar demographic properties, hemoglobin A1c values and clinical severity of macular edema (12/25 vs 12/15 :p=0.056). In total, 12 patients (30%) developed intraocular pressure (IOP) elevations at 1 to 4 weeks, which were controlled by glaucoma medications.


Intravitreal injection is of benefit in eyes with diffuse diabetic macular edema, especially for eyes without prior laser photocoagulation. Medically controllable IOP elevations are not rare.